Dhh1 is a member of the SESA network

The correct separation of chromosomes during mitosis is necessary to prevent genetic instability and aneuploidy, which are responsible for cancer and other diseases, and it depends on proper centrosome duplication. In a recent study, we found that Smy2 can suppress the essential role of Mps2 in the insertion of yeast centrosome into the nuclear membrane by interacting with Eap1, Scp160, and Asc1 and designated this network as SESA (S my2, E ap1, S cp160, A sc1). Detailed analysis showed that the SESA network is part of a mechanism which regulates translation of POM34 mRNA. Thus, SESA is a system that suppresses spindle pole body duplication defects by repressing the translation of POM34 mRNA. In this study, we performed a genome-wide screening in order to identify new members of the SESA network and confirmed Dhh1 as a putative member. Dhh1 is a cytoplasmic DEAD-box helicase known to regulate translation. Therefore, we hypothesized that Dhh1 is responsible for the highly selective inhibition of POM34 mRNA by SESA.     

Use of Warranties on Highway Projects: A Real Option Perspective

Since the introduction of warranty provisions in federal highway jobs, more and more state departments of transportation (DOTs) have considered the use of such provisions to protect their initial investment. This paper describes the pros and cons of warranty contracting in highway construction based on a survey of warranty practices in the United States. In particular, the need for state DOTs to buy a warranty for a well-built project is questioned. As an alternative, this paper introduces the warranty option, which gives the DOT the right to buy a warranty only if it becomes necessary at the end of construction. This option is exercised if the performance on site warrants it. This paper describes the mechanics of the warranty option and its advantages over the conventional warranty. A bid evaluation model is also developed for the warranty option approach.     

Pharmacokinetics of phenprobamate after oral administration to healthy subjects

Phenprobamate (CAS 673-31-4) is a centrally acting skeletal-muscle relaxant agent. There are only two studies in the literature about the pharmacokinetics of phenoprobamate in man. The inconsistency between the results of these studies can be attributed partly to the different analytical methodologies used. A sensitive, specific and reproducible HPLC-assay, which may increase the reliability of the pharmacokinetic studies of phenprobamate in plasma, has been developed recently. The objective of this investigation was to assess the single-dose kinetics of phenprobamate in human and to determine the pharmacokinetic parameters of clinical and regulatory concern. The plasma pharmacokinetics of phenprobamate have been investigated following single oral administration at a dose of 800 mg in eleven healthy volunteers.     

A New Recycled Al–Si–Mg Alloy for Sustainable Structural Die Casting Applications

Metallurgical and Materials Transactions A - The use of secondary aluminum for structural components in the automotive industry is limited by the high Fe contents in recycled alloys which often...     

Persistence Heterogeneity Testing in Panels with Interactive Fixed Effects

We consider large N,T panel data models with fixed effects, a common factor allowing for cross‐section dependence, and persistent data and shocks, which are assumed fractionally integrated. In a basic setup, the main interest is on the fractional parameter of the idiosyncratic component, which is estimated in first differences after factor removal by projection on the cross‐section average. The pooled conditional‐sum‐of‐squares estimate is consistent but the normal asymptotic distribution might not be centred, requiring the time series dimension to grow faster than the cross‐section size for correction. We develop tests of homogeneity of dynamics, including the degree of integration, that have no trivial power under local departures from the null hypothesis of a non‐negligible fraction of cross‐section units. A simulation study shows that our estimates and tests have good performance even in moderately small panels.     

Unveiling the presence of mixed oxidation states of Europium in Li7+δEuxLa3−δZr2−δO12−δ garnet and its impact on the Li-ion conductivity

Recently, lanthanides have been employed by researchers to examine their impact on the structure and properties of Li₇La₃Zr₂O₁₂ (LLZO) garnets. In this regard, we developed Europium oxide (Eu₂O₃) doped LLZO (Li_7+δEu_xLa_3−δZr_2−δO_12−δ) solid electrolyte which demonstrates a cubic phase with the symmetry of Iad (No.230) at room temperature. In this investigation, different concentrations of Eu ranging from 0.1 to 0.6 atoms per formula unit (pfu) were doped into Li₇La₃Zr₂O₁₂ to evaluate the impact of Eu on the stability of the cubic phase and thereby the ionic conductivity. The results unveiled that upon doping Eu³⁺ ions, the Eu²⁺ state is also formed and is then self-doped into the structure in which Rietveld refinement coupled with XPS, EPR, and solid-state NMR suggests that Eu³⁺ ions most probably partially occupy Zr⁴⁺ (16a) site, the Eu²⁺ ions occupy La³⁺ (24d) site, and the Li⁺ ions occupy two different sites (24d and 96h). It was further found that such a site preference induces distortion at LaO₈ polyhedrons opening up the neck for Li-ions diffusion, thereby enhancing the ionic conductivity. Moreover, it was revealed that Li-ions probably hop from 96h to 24d and then to 96h site to generate the Li-ion movement. Overall, by introducing Eu ions into the LLZO structure, an enhanced bulk ionic conductivity of 0.30 × 10⁻³ S/cm at 298 K with a minimum electronic conductivity of 2.547 × 10⁻⁹ S/cm at 298 K was achieved.